Stock Under $10 with 50-100% upside potential - 14 Days FREE!

10 Best Biotech Stocks for 2013

Top Rated Stocks

Every day TheStreet Ratings produces a list of the top rated stocks, by industry. The following biotech stocks are rated highest by our value-focused model. This list will be updated as upgrades and downgrades occur.

Equity Top: Biotechnology


Source: TheStreet Ratings

Best Investments for 2013

Biotechnology News

Article
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
5/17/13 7:00AM
Video
TheStreet senior columnist Adam Feuerstein discusses the winners and losers from the research abstracts ahead of the ASCO cancer conference.
5/16/13 2:09PM
Article
Here's why Stimuvax didn't help lung cancer patients live longer.
5/15/13 6:00PM
Article
Get a head start on searching through ASCO abstracts with these 10 summaries.
5/15/13 6:00PM
Article
New data suggests Roche's GA101 is more potent than the blockbuster Rituxan.
5/15/13 6:00PM
Article
More than half of patients responded to treatment with Gilead's idelalisib in a phase I study.
5/15/13 6:00PM
Article
A new class of immune-boosting drugs are showing great promise against melanoma, lung and kidney cancers.
5/15/13 6:00PM
Article
Regulators have issued a subpoena to Spectrum for information related to the steep cut in Fusilev sales in 2013.
5/13/13 7:19AM
Article
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
5/10/13 7:00AM
Video
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
5/9/13 9:39AM
Article
A New York fertility doctor accuses Repros CEO of stealing the idea for a new oral testosterone therapy.
5/9/13 8:00AM
Article
Fish oil supplements have no heart benefits for patients, which doesn't bode well for Amarin's efforts to market Vascepa.
5/9/13 12:15AM
Article
Osiris CEO claims Prochymal is most widely used stem cell drug in world yet has generated no sales -- ever.
5/7/13 1:19PM
Article
DEA finalizes Belviq abuse schedule, allowing the weight-loss pill launch in June.
5/7/13 11:53AM
Article
Heads need to roll at Aveo because of the FDA's thrashing of the company's kidney cancer drug.
5/6/13 12:26PM

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
TRY IT FREE

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Dividend Stock Advisor
TRY IT FREE
New! $49.95/yr

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Real Money
TRY IT FREE

24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.

Product Features:
  • Jim Cramer + 20 Wall Street pros
  • Intraday commentary & news
  • Real-time trading forum
  • Actionable trade ideas
Real Money Pro
TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass + 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 15,354.40 121.18 0.80%
NASDAQ 3,498.97 33.73 0.97%
S&P 500 1,667.47 17.00 1.03%
US 10 Yr 1.949% +0.084

Brokerage Partners

Advertising Partners

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.

Top Rated Stocks Top Rated Funds Top Rated ETFs